

PO-287: Do elderly patients with migraine have the same effectiveness and tolerability to galcanezumab in Real World Evidence (RWE)? Series of 40 cases in Galca-Only Consortium.

Victor Obach¹, Rocio Alvarez-Escudero², Nuria Riesco², Alba Bravo³, Marta Ruibal⁴, Ane Minguez⁴, Fernando Velasco⁵, Izaro Kortazar⁶, Amaya Echeverria⁶, Elisa Cuadrado⁷, Sonsoles Aranceta⁸, Santiago Fernandez-Fernandez¹, Neus Fabregat¹, Teresa Marco¹, Juan Carlos Garcia-Monco⁹, Aintzine Ruisanchez¹⁰, David Garcia-Azorin¹¹.

¹Hospital Clinic, Barcelona, Spain. ²Hospital Central de Asturias, Oviedo, Spain. ³Hospital Reina Sofia, Tudela, Spain. ⁴Hospital de Donosti, San Sebastian, Spain. ⁵Hospital Cruces, Bilbao, Spain. ⁶Hospital Txagorritxu, Alava, Spain. ⁷Hospital del Mar, Barcelona, Spain. ⁸Hospital Tauli, Sabadell, Spain. ⁹Hospital de Basurto, Bilbao, Spain. ¹⁰Hospital Galdakao, Bilbao, Spain. ¹¹Hospital de Valladolid, Valladolid, Spain

OBJECTIVE

Patient over 70 years old with migraine are underrepresented in anti CGRP monoclonal antibody clinical trials. We analyze the tolerability and effectiveness of galcanezumab in this group of patients from a large multicentre registry.

METHODS

The “Galca-Only Consortium” is a multicenter ambispective cohort study. All consecutive patients with chronic migraine or high-frequency episodic migraine with prior failure to three or more migraine preventive drugs, treated with galcanezumab were included.

Patients were systematically assessed by headache experts and followed up quarterly for 12 months.

Response to treatment was defined as the proportion of patients who achieved a reduction of at least 50% (R50) in the number of headache days per month, compared to the baseline period. Tolerability was assessed as the proportion of patients who discontinued the treatment due to inadequate tolerability. Data of follow-up at 12 months are presented.

In the present sub-analysis, patients older than 70 years old were compared with the younger cohort.

RESULTS

Study period: 15th November 2019 to 31st January 2022. In the registry of 1055 patients, 46 patients (4.4%) were older than 70 years old.

The proportion of men is higher than in the younger group. They also presented higher number of MHDs and history of longer period of migraine worsening.

At 12 month follow-up, the R50 was 47.8% similar to 41.0% in the younger group. No differences were observed in Galcanezumab retention rate 65.2% and 71.6% and discontinuation due to adverse events 8.7% and 6.5%, respectively.

CONCLUSION

The effectiveness and safety of galcanezumab in migraine patients over 70 years old in RWE is similar to younger patients.

Table1. Demographics of the study population.

| | Patients over 70 years old n=46 | Patients 18 to 69 years old n=1009 | P value |
|--|------------------------------------|---------------------------------------|---------|
| Age, mean (SD) | 74.8 (4.5) | 48.6 (11.0) | 0.001 |
| Female, n (%) | 31 (67.4) | 844 (83.6) | 0.006 |
| Migraine worsening, years [IQR] | 12 [7-21] | 8 [4-13] | 0.001 |
| Chronic migraine, n (%) | 40 (87.0) | 766 (75.9) | 0.08 |
| Monthly Headache Days (MHDs), baseline [IQR] | 30 [16-30] | 20 [14-20] | 0.008 |
| Monthly Daily Headache (30 Days), n (%) | 24 (52.2) | 324 (32.1) | 0.005 |
| HIT6 baseline [IQR] | 71 [67-74] | 68 [65-72] | 0.12 |
| Mental disorders, n (%) | 11 (30.6.9) | 335 (39.7) | 0.3 |
| Chronic pain syndrome, n (%) | 11 (30.6) | 195 (23.1) | 0.3 |